恆泰艾普(300157.SZ):擬向銀行或其他主體申請不超1億元借款並接受關聯方擔保
格隆匯11月11日丨恆泰艾普(300157.SZ)公佈,為落實公司發展戰略,滿足公司持續經營以及化解短期償債壓力對資金的需求,公司擬向銀行或其他主體申請借款,本次借款事項具體情況如下:
公司擬向銀行或其他主體申請不超過人民幣1億元借款,借款期限不超過12個月,具體內容以公司與相關主體實際簽署的文件為準。公司實際控制人李麗萍及其一致行動人王瀟瑟擬為公司辦理上述借款提供擔保,公司及合併範圍內主體無需向公司實際控制人及其一致行動人支付相關擔保費用。為提高工作效率,及時辦理融資業務,董事會授權公司管理層簽署相關文件,包括但不限於借款、擔保等有關的申請書、合同、協議等文件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.